Contact Us |

Search 

עברית  

    logoemp

 

slogN

 

 

dayanews emp nodaya

 

27 | October | 2014

Case Western Reserve University to Study Pluristem’s PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases

Read more >


21 | October | 2014

Pluristem Advances its Second Major Cell Therapy Product Line from Development to Large-Scale Manufacturing

Read more >


10 | October | 2014

Pluristem (Nasdaq: PSTI) will announce its first quarter 2015 financial results (July-September 2014),  on Thursday, November 6th, 2014, after the market close

 


07 | October | 2014

Pluristem Wins Cell Therapy Patent Case in Europe; European Patent Office Confirms Validity of Amended Claims

Read more >


16 | September | 2014

Pluristem Pursues Development Strategy in Japan Where New Law Accelerates Path to Market

Read more >


10 | September | 2014

Pluristem to Deliver Scientific Presentations at 3rd International Placenta Stem Cell Society Meeting

Read more >

 
 
 
About hp
 

Zami Aberman

Chairman and CEO

 

Zami Aberman

   From the CEO

Our vision at Pluristem Therapeutics is to leverage our position as a global leader in placenta-based cell science to become the world’s leader in developing and manufacturing cell therapy products. We believe our cutting edge technology can produce therapies that will become the standard of care for treating a host of inflammatory and ischemic conditions. We also believe “the process is the product.” This reflects our view that precise control of the entire process, from obtaining cells from the source, to delivery to the patient, is vital to the success of a cell therapy product. Our fully automated process, proprietary 3D cell expansion technology and increasing knowledge of the placental cell drive us towards the development of additional product candidates for new indications and markets.

 

On July 23 we hosted a Key Opinion Leader breakfast in New York. Dr. Baha Sibai, a world renowned expert in preeclampsia, Director of the Maternal-Fetal Medicine Fellowship Program and a Professor in the Department of Obstetrics and Gynecology at University of Texas Health Science Center, spoke about this serious complication of pregnancy, its heavy costs to society, and the potential of cell therapy to treat it. This tremendous unmet medical need makes this indication one of our top priorities at Pluristem and we are hopeful that the strong preclinical data we have accumulated using PLX-PAD in preeclampsia will translate into similar results in the clinic. If you would like to learn more about preeclampsia and Pluristem’s preeclampsia program, the recording of the webcast from the KOL event is above.

Zami Aberman
Chairman and CEO 

 

 

 

Share Button comm

  
Investors hp
 

     Yaky Yanay
     President and COO

 

Yaky Yanay

Pluristem's wholly owned subsidiary, Pluristem Ltd., has received approval for a 14.6 million New Israeli Shekel (approximately $ 4.2 million) grant from the Office of the Chief Scientist (OCS) within the Israeli Ministry of Economy. Once received, the grant will be used to cover R&D expenses for the period January 2014 to December 2014.

 

Read more >> 
 
 

Share Button comm

tech hp
 

Hillit Mannor Shachar, M.D., M.B.A.
VP Business Development

 

Hillit Mannor Shachar

Pluristem Pursues Development Strategy in Japan Where New Law Accelerates Path to Market

Pluristem is evaluating strategic opportunities to co-develop and commercialize its PLacental eXpanded (PLX) cell therapies in Japan.

Read more >>

 
 

Share Button comm

 
 
Investors hp
 

        Boaz Gur-Lavie,         C.P.A., M.B.A.
        CFO 

 

boaz-new

Pluristem released its 10-K and consolidated financial statements for the year ended on June 30th, 2014.

 

Read more >>
 
 

Share Button comm

 catom 01

catom 03

catom 05

catom 07

catom 09

catom 11

catom 13

 

 

 

catom 02

Share Button